The Final Efficacy Of The Sputnik V Vaccine Has Been Disclosed

The Final Efficacy Of The Sputnik V Vaccine Has Been Disclosed
The Final Efficacy Of The Sputnik V Vaccine Has Been Disclosed

Video: The Final Efficacy Of The Sputnik V Vaccine Has Been Disclosed

Video: Russia's Sputnik V vaccine: What the experts say | COVID-19 Special 2022, November
Anonim
Image
Image

The results of the final third phase of clinical trials of the Russian vaccine Sputnik V demonstrated 91.6% efficacy against SARS-CoV-2. The conclusions, which are reported in a press release received by the editorial board of "Lenta.ru", are disclosed in the leading medical journal Lancet.

19,866 people took part in testing the vaccine, who received the first and second doses of the drug or placebo. By the end of the study, 78 cases of COVID-19 had been reported. For people over 60 years of age, the effectiveness of Sputnik V was 91.8 percent, which did not differ statistically from the data obtained in a group of volunteers from 18 to 60 years old.

It is noted that the vaccine provides full protection against severe cases of coronavirus infection. Severe COVID-19 developed in only 20 people who received a placebo. 98 percent of the subjects developed humoral immunity, and 100 percent - cellular immunity. At the same time, the level of neutralizing antibodies in those who have been vaccinated is higher than in those who have been ill.

“The world currently needs all the good COVID-19 vaccines it can get. And these are impressive results: Sputnik V is the first human adenovirus vector vaccine to hit the 90 percent efficacy threshold, like two other mRNA vaccines,”said University of East Anglia professor of medical microbiology David Livermore.

Most of the side effects were mild and were expressed as general malaise, headache, low fever and reactions at the injection site. There are no severe allergic reactions, including anaphylactic shock.

Popular by topic